Detroit, MI 的 乳癌 臨床試驗
33 項針對 乳癌 的研究正在 Detroit（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
招募中2 期
- Henry Ford Hospital, Detroit
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
招募中3 期
- Henry Ford Health ( Site 0002), Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Detroit
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
招募中
- Karmanos Cancer Center - Wayne State University, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
招募中1 期
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
招募中1 期
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
招募中3 期
- Henry Ford Hospital, Detroit
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
招募中1/2 期
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion BHCP, Detroit
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
招募中3 期
- Karmanos Cancer Center, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
招募中1/2 期
- Henry Ford Hospital, Detroit
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
招募中3 期
- Henry Ford Health System, Detroit
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
招募中
- Karmanos Cancer Institute, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
招募中3 期
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
E-Mindfulness Approaches for Living After Breast Cancer
招募中3 期
- Henry Ford Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Karmanos Cancer Institute, Detroit
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
招募中歡迎健康志工
- Henry Ford Health, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Henry Ford Health Hospital, Detroit
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
招募中1/2 期
- Henry Ford Hospital, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
招募中3 期
- Henry Ford Health System, Detroit
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of the TheraBionic P1 Device in Breast Cancer
招募中
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
招募中1/2 期
- Karmanos Cancer Institute, Detroit
F-Tryptophan PET/CT in Human Cancers
招募中1 期
- Karmanos Cancer Institute, Detroit
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
招募中3 期
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
招募中
- Karmanos Cancer Institute, Detroit
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Detroit 的其他研究
- 非小細胞肺癌44 項研究
- 癌症（所有類型）29 項研究
- 大腸直腸癌26 項研究
- 卵巢癌26 項研究
- 轉移性癌症24 項研究
- 前列腺癌22 項研究
- 子宮內膜癌21 項研究
- 肺癌20 項研究
- 多發性骨髓瘤19 項研究
- 胃癌16 項研究
- 頭頸部鱗狀細胞癌15 項研究
- 急性髓系白血病14 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。